Patients with chromosome 13q deletion or normal cytogenetics represent the majority of chronic lymphocytic leukaemia (CLL) cases, yet have relatively few driver mutations. To better understand their genomic landscape, here we perform whole-genome sequencing on a cohort of patients enriched with these cytogenetic characteristics. Mutations in known CLL drivers are seen in only 33% of this cohort, and associated with normal cytogenetics and unmutated IGHV. The most commonly mutated gene in our cohort, IGLL5, shows a mutational pattern suggestive of activation-induced cytidine deaminase (AID) activity. Unsupervised analysis of mutational signatures demonstrates the activities of canonical AID (c-AID), leading to clustered mutations near active...
Chronic lymphocytic leukaemia (CLL) is characterised by a chronically relapsing course and clinical ...
Over the past few years, several large-scale studies using next-generation sequencing (NGS) of whole...
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and the...
Patients with chromosome 13q deletion or normal cytogenetics represent the majority of chronic lymph...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
ABSTRACT Sequencing studies have been instrumental in understanding the genetic basis of chronic lym...
Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes de...
Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes de...
Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes de...
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and the...
Disease progression in IGHV-M CLL with 'good-risk' cytogenetics is frequently associated with co-evo...
Chronic lymphocytic leukaemia (CLL) is characterised by a chronically relapsing course and clinical ...
Over the past few years, several large-scale studies using next-generation sequencing (NGS) of whole...
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and the...
Patients with chromosome 13q deletion or normal cytogenetics represent the majority of chronic lymph...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer pa...
ABSTRACT Sequencing studies have been instrumental in understanding the genetic basis of chronic lym...
Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes de...
Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes de...
Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes de...
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and the...
Disease progression in IGHV-M CLL with 'good-risk' cytogenetics is frequently associated with co-evo...
Chronic lymphocytic leukaemia (CLL) is characterised by a chronically relapsing course and clinical ...
Over the past few years, several large-scale studies using next-generation sequencing (NGS) of whole...
Which genetic alterations drive tumorigenesis and how they evolve over the course of disease and the...